Carly Levine

Carly Levine is an Associate at the AMR Action Fund (AMRAF), where she is responsible for evaluating innovative technologies, cultivating investment opportunities, and supporting the fund’s portfolio companies. She joined AMRAF as an Analyst in November 2021. With approximately US$1 billion under management, AMRAF is the largest antimicrobial-focused venture fund. During her time at AMRAF, Dr. Levine has helped guide numerous investments into biotech companies that are developing therapeutics for priority drug-resistant pathogens. Prior to joining AMRAF, she spent nearly a decade in academia, where she developed a deep understanding of the biology of drug resistance and the science that underpins novel antimicrobial development. Dr. Levine’s research focused primarily on evaluating novel anti-tubercular drug candidates and applying a multi-omics approach to characterize the physiology of drug-tolerant Mycobacterium tuberculosis isolates. She is a Board Observer at Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.